Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

4.48
+0.580014.87%
Post-market: 4.490.0100+0.22%19:59 EDT
Volume:11.60M
Turnover:51.33M
Market Cap:1.34B
PE:-7.89
High:4.70
Open:3.95
Low:3.94
Close:3.90
Loading ...

AbCellera Biologics Is Maintained at Overweight by Keybanc

Dow Jones
·
14 Jul

Abcellera Biologics Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
08 Jul

AbCellera Biologics Coverage Assumed by Leerink Partners at Outperform

Dow Jones
·
07 Jul

Village Farms International And 2 Other Promising Penny Stocks For Your Watchlist

Simply Wall St.
·
05 Jul

AbCellera Biologics Inc. Concluded Annual Shareholders Meeting

Reuters
·
14 Jun

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Motley Fool
·
03 Jun

AbCellera Biologics Receives Health Canada Approval for Trial

TIPRANKS
·
31 May

AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575

Reuters
·
31 May

Abcellera Receives Authorization From Health Canada to Initiate a Phase 1 Clinical Trial of Abcl575

THOMSON REUTERS
·
31 May

AbCellera Biologics Is Maintained at Buy by Truist Securities

Dow Jones
·
17 May

Truist Financial Remains a Buy on AbCellera Biologics (ABCL)

TIPRANKS
·
16 May

Abcellera Biologics Inc : Truist Securities Cuts Target Price to $10 From $28

THOMSON REUTERS
·
16 May

AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment

MT Newswires Live
·
15 May

AbCellera Biologics Receives Health Canada Approval for Trial

TIPRANKS
·
15 May

AbCellera receives NOL from Health Canada for ABCL635 clinical trial application

TIPRANKS
·
15 May

BRIEF-AbCellera Receives Authorization From Health Canada To Initiate The Phase 1 Clinical Trial Of Abcl635 For Vasomotor Symptoms Due To Menopause

Reuters
·
15 May

AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes

Reuters
·
15 May

Abcellera Biologics Inc - Phase 1 Trial for Abcl635 Expected to Start in Q3 2025

THOMSON REUTERS
·
15 May

Abcellera Receives Authorization From Health Canada to Initiate the Phase 1 Clinical Trial of Abcl635 for Vasomotor Symptoms Due to Menopause

THOMSON REUTERS
·
15 May

AbCellera Biologics Says Federal Circuit Upholds PTAB's Validity Judgment on Microfluidic Cell Culture Patent

MT Newswires Live
·
13 May